1149 related articles for article (PubMed ID: 25159157)
1. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
2. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
Sixdorf U; Bauer H; Märker-Hermann E
Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
[TBL] [Abstract][Full Text] [Related]
3. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Dittrich K; Ross S; Benz K; Amann K; Dötsch J
Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565
[TBL] [Abstract][Full Text] [Related]
4. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
Ginzler EM; Wofsy D; Isenberg D; Gordon C; Lisk L; Dooley MA;
Arthritis Rheum; 2010 Jan; 62(1):211-21. PubMed ID: 20039429
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Buratti S; Szer IS; Spencer CH; Bartosh S; Reiff A
J Rheumatol; 2001 Sep; 28(9):2103-8. PubMed ID: 11550982
[TBL] [Abstract][Full Text] [Related]
7. [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
Kise T; Yoshimura H
Nihon Jinzo Gakkai Shi; 2012; 54(2):86-93. PubMed ID: 22590961
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
Dall'Era M
Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
[TBL] [Abstract][Full Text] [Related]
9. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
12. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
F L; Y T; X P; L W; H W; Z S; H Z; Z H;
Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.
Wilson EC; Jayne DR; Dellow E; Fordham RJ
Rheumatology (Oxford); 2007 Jul; 46(7):1096-101. PubMed ID: 17409128
[TBL] [Abstract][Full Text] [Related]
14. [Mycophenolate mofetil maintenance therapy in lupus nephritis].
Milewski M; Jakieła B; Zółciński M; Chmielewska A; Musiał J
Pol Arch Med Wewn; 2006 Oct; 116(4):947-54. PubMed ID: 18416296
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil for lupus nephritis: an update.
Mok CC
Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
20. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan.
Hara R; Miyazawa H; Nishimura K; Momoi T; Nozawa T; Kikuchi M; Sakurai N; Kizawa T; Shimamura S; Yasuda S; Hiromura K; Sada KE; Kawaguchi Y; Tamura N; Takei S; Takasaki Y; Atsumi T; Mori M
Mod Rheumatol; 2015; 25(6):858-64. PubMed ID: 26215483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]